Posts

A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.

/by

Authors: Elizabeth Steels, Ruchitha Venkatesh, Eleanor Steels, Gemma Vitetta, Luis Vitetta
Inflammopharmacology, June 2019
—
BACKGROUND: The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis. METHODS: This was a single site, comparative, double-blind placebo controlled study i…

Read more

Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with osteoarthritis: a pilot study.

/by

Authors: Carmela Valastro, Debora Campanile, Mariarosaria Marinaro, Delia Franchini, Fabiana Piscitelli, Roberta Verde, Vincenzo Di Marzo, Antonio Di Bello
BMC Veterinary Research, 6 November 2017
—
BACKGROUND: Cannabis-based drugs have been shown to be effective in inflammatory diseases. A number of endocannabinoids including N- arachidonoylethanolamide (anandamide, AEA) and 2-arachidonyl glycerol (2-AG) with activity at the cannabinoid receptors (CBR) CBR1 and CBR2, hav…

Read more

Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint.

/by

Authors: James J. Burston, Devi Rani Sagar, Pin Shao, Mingfeng Bai, Emma King, Louis Brailsford, et al
PLoS One, 25 November 2013
—
Osteoarthritis (OA) of the joint is a prevalent disease accompanied by chronic, debilitating pain. Recent clinical evidence has demonstrated that central sensitization contributes to OA pain. An improved understanding of how OA joint pathology impacts upon the central processi…

Read more